Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
3.890
+0.100 (2.64%)
At close: Jul 20, 2026, 4:00 PM EDT
3.937
+0.047 (1.21%)
Pre-market: Jul 21, 2026, 4:43 AM EDT

Virax Biolabs Group Income Statement

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
0.010.010.160.01-
Revenue Growth (YoY)
96.23%-95.95%1727.11%--
Cost of Revenue
00.060.110.01-
Gross Profit
0.01-0.050.05-0-
Selling, General & Admin
2.673.994.573.551.3
Research & Development
3.742.031.612.180.43
Other Operating Expenses
--0.39--
Total Operating Expenses
6.416.026.585.731.73
Operating Income
-6.4-6.08-6.53-5.73-1.73
Total Non-Operating Income (Expense)
0.59-0.050.27-0.270.02
Pretax Income
-5.93-6.2-6.74-5.46-1.75
Provision for Income Taxes
-0.9-0.14---
Net Income
-5.03-6.07-6.74-5.46-1.75
Minority Interest in Earnings
-0.01-0.01-0.01-0-0.04
Net Income to Common
-5.02-6.06-6.73-5.46-1.71
Shares Outstanding (Basic)
00000
Shares Outstanding (Diluted)
00000
Shares Change (YoY)
166.46%85.92%88.75%11.15%504.72%
EPS (Basic)
-12.64-40.62-83.90-128.25-44.75
EPS (Diluted)
-12.64-40.62-83.90-128.25-44.75
Free Cash Flow
-4.88-5.17-7.35-4.18-0.81
Free Cash Flow Per Share
-12.27-34.63-91.57-98.30-21.15
Gross Margin
61.90%-838.21%32.34%-15.94%-
Operating Margin
-51515.20%-95984.90%-4171.92%-66963.70%-
Profit Margin
-40507.00%-95833.70%-4308.38%-63751.50%-
FCF Margin
-39263.60%-81621.60%-4698.55%-48823.40%-
EBITDA
-6.04-5.81-6.47-5.73-1.73
EBITDA Margin
-48607.40%-91773.80%-4136.84%-66963.70%-
EBIT
-6.4-6.08-6.53-5.73-1.73
EBIT Margin
-51515.20%-95984.90%-4171.92%-66963.70%-
Effective Tax Rate
15.17%2.20%0.00%0.00%0.00%
SEC Filings: 10-K · 10-Q